Novo Nordisk A/S Novo Nordisk A/S - Press Releases Novo Nordisk A/S - Press Releases Phase 3a data from largest trial with liraglutide 3 mg demonstrated significantly greater weight loss versus placebo for adults with obesity NovoEight® provides long-term reduction of bleeding in people with haemophilia A New model needed in diabetes care Novo Nordisk launches ’Cities Changing Diabetes’ to fight urban diabetes Tresiba® and Victoza® receive positive opinions from CHMP for label updates expanding indications for use in adults with type 2 diabetes Novo Nordisk invests 550 million Danish kroner in new purification pilot plant in Denmark Novo Nordisk files annual report with the SEC Innate Pharma acquires full rights to anti-NKG2A checkpoint inhibitor from Novo Nordisk A/S Novo Nordisk publishes its 2013 Annual Report Novo Nordisk launches its shortest needle: NovoFine® Plus, compatible with all major pen devices World’s first all-diabetes professional cycling team gears up for season’s first race with new line-up FDA approves TRETTEN® for the treatment of congenital factor XIII A-subunit deficiency Novo Nordisk reported to the police by the Danish Financial Supervisory Authority for violating disclosure obligation Only 29% of people with diabetes report that their doctors ask them for input for their own treatment plans Ryzodeg® offers improved glycaemic control with significantly lower rates of hypoglycaemia compared to biphasic insulin aspart 30 in adults with type 2 diabetes1 IDegLira demonstrates superior glycaemic control and weight loss with a low rate of hypoglycaemia for patients uncontrolled on basal insulin* Novo Nordisk and Roche Diabetes Care are joining forces to make insulin pump therapy simpler for people with diabetes NovoEight® passed the review by the Committee on Drugs of Pharmaceutical Affairs in Japan Novo Nordisk and Oxford University join forces to further enhance diabetes research Novo Nordisk receives FDA approval for FlexTouch® in the US